ISRCTN57145331进行中（未招募）2 期
A randomised, double-blind, placebo-controlled, phase 2 evaluation of the efficacy and mechanism of trientine in patients with hypertrophic cardiomyopathy
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 152
研究概览
简要总结
2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37137675/ (added 04/05/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Written informed consent given
- •2. Aged between 18 and 75 years inclusive (Updated 07/11/2023: previously between 18 and 70 years inclusive)
- •3. Hypertrophic cardiomyopathy (HCM), as defined by the European Society of Cardiology HCM guidelines as: a wall thickness > = 15 mm in one or more LV myocardial segments that is not explained solely by loading conditions”. The same definition is applied to first-degree relatives of patients with HCM i.e. all participants are required to have a LV wall thickness > = 15 mm. Wall thickness is as measured on the most recent cardiovascular magnetic resonance (CMR) scan performed prior to the baseline visit. If CMR has not been performed previously, wall thickness measurement should be taken from the most recent echocardiogram performed prior to the baseline visit. (It is recognised that in the European Society of Cardiology guidelines a clinical diagnosis of HCM in first-degree relatives requires a wall thickness that is less than this value, however > = 15 mm is applied here in order to ensure that all participants have an unequivocal phenotype).
- •4. New York Heart Association class I, II or III at the most recent clinical assessment performed prior to the baseline visit
排除标准
- •1. Previous or planned septal reduction therapy
- •2. Previously documented myocardial infarction or severe coronary artery disease
- •3. Uncontrolled hypertension, defined as a systolic blood pressure of >180 mmHg or diastolic blood pressure of >100 mmHg at visit 1
- •4. Known LV EF <50%, as measured on the most recent CMR scan performed prior to the baseline visit. If CMR has not been performed previously, the most recent echocardiogram performed prior to the baseline visit should be used.
- •5. Previously documented persistent atrial fibrillation
- •6. Anaemia, defined as haemoglobin being below the local site normal reference range, at visit 1
- •7. Iron deficiency, defined as serum iron being below the local site normal reference range, at visit 1
- •8. Copper deficiency, defined as serum copper being below the normal reference range, at visit 1
- •9. Pacemaker or implantable cardioverter-defibrillator
- •10. Known severe valvular heart disease, as demonstrated on the most recent heart imaging performed prior to the baseline visit
- •11. Previously documented other cardiomyopathic cause of myocardial hypertrophy (e.g. amyloidosis, Fabry disease, mitochondrial disease)
- •12. History of hypersensitivity to any of the components of the investigational medicinal product (IMP)
- •13. Known contraindication to MRI scanning
- •14. Pregnancy, lactation, or planning pregnancy. Women of childbearing capacity are required to have a negative serum pregnancy test before treatment, must agree to pregnancy tests at study visits as defined in the Section 8, and must agree to maintain highly effective contraception as defined in Section 8 during the study.
- •15. Any medical condition, which in the opinion of the Investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study
研究者
相似试验
已完成
3 期
Phase III trial of inhaled SNG001 compared to placebo for the treatment of patients hospitalised due to moderate COVID-19COVID-19 (SARS-CoV-2 infection)Infections and InfestationsISRCTN85436698Synairgen Research Ltd623
已完成
不适用
Evaluation of immune modulation by beta-glucan, a soluble dietary fiber derived from reishi mushroom in healthy adult volunteers, a systemic clinical trialISRCTN48306294Super Beta Glucan Inc., Biomedical Research Division173
已完成
3 期
A study to evaluate if different doses of KVD900 are safe and effective in treating attacks in patients with hereditary angioedemaHereditary angioedema (HAE) type I or type II.Haematological DisordersHereditary Angioedema Type I or IIISRCTN14762022KalVista Pharmaceuticals Ltd136
已完成
不适用
Pramipexole trial for bipolar depressioTreatment-resistant bipolar depressionMental and Behavioural DisordersBipolar affective disorderISRCTN72151939Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust90
已完成
不适用
Evaluation of Dermasectan® versus SoC to compare efficacy and safety in treating atopic eczema (dermatitis) in adultsSkin and Connective Tissue DiseasesAtopic dermatitisISRCTN66879853ovintethical Pharma (Switzerland)42